ABG Interpretation and Management

Systematic Approach to Interpretation

• The American Thoracic Society recommends interpreting ABG results using a three-step systematic approach: first evaluate pH to determine acidemia or alkalemia, then examine PaCO2 to identify the respiratory component, and finally evaluate base excess/bicarbonate to identify the metabolic component 1, 2
• A pH < 7.35 indicates acidemia, while a pH > 7.45 indicates alkalemia 1
• PaCO2 > 45 mmHg with low pH indicates respiratory acidosis, while PaCO2 < 35 mmHg with high pH indicates respiratory alkalosis 1, 3
• Base excess < -2 or HCO3 < 22 indicates metabolic acidosis, while base excess > +2 or HCO3 > 26 indicates metabolic alkalosis 2, 4

Primary Indications for ABG Testing

• The American College of Physicians recommends ABG testing for all critically ill patients to assess oxygenation, ventilation, and acid-base status 1, 2
• ABG testing is also recommended for patients with shock or hypotension, oxygen saturation fall below 94% on room air or supplemental oxygen, and deteriorating oxygen saturation or increasing breathlessness in patients with previously stable chronic hypoxemia 1, 2
• The European Respiratory Society recommends ABG testing for suspected diabetic ketoacidosis, metabolic acidosis from renal failure, trauma, shock, and sepsis 1, 2, 4

Management of Abnormal ABG Results

• The British Thoracic Society recommends initiating non-invasive ventilation (NIV) for acute hypercapnic respiratory failure with pH < 7.35 and PaCO2 > 6.5 kPa (49 mmHg) despite optimal medical therapy 3
• Controlled oxygen therapy targeting SpO2 88-92% is recommended for COPD and all causes of acute hypercapnic respiratory failure 3
• The American Thoracic Society recommends repeating ABG after each titration to monitor for worsening hypercapnia 1, 2

Special Populations

• The Global Initiative for Chronic Obstructive Lung Disease recommends checking ABG when starting oxygen in COPD patients, especially with known CO2 retention 1, 2
• The European Association for the Study of the Liver recommends using P(A-a)O2 ≥ 20 mmHg cutoff instead of ≥ 15 mmHg for hepatopulmonary syndrome diagnosis in patients aged ≥ 65 years 5
• The American Association for the Study of Liver Diseases recommends PaO2 < 80 mmHg or P(A-a)O2 ≥ 15 mmHg (≥ 20 mmHg if age ≥ 65) for hepatopulmonary syndrome diagnosis 5

Management of Mixed Respiratory and Metabolic Acidosis

Diagnosis and Initial Management

• The British Thoracic Society and Intensive Care Society guidelines recommend non-invasive ventilation (NIV) for patients with pH <7.35 and PCO2 ≥6.5 kPa, as seen in this patient with a pH of 7.14 and PCO2 of 54.2 mmHg 6, 7
• The patient's PCO2 of 54.2 mmHg indicates respiratory acidosis, requiring immediate NIV and treatment of the underlying metabolic acidosis 6, 7
• The patient is on supplemental oxygen with a PO2 of 283 mmHg, indicating adequate oxygenation 8

Ventilation Parameters

• The European Respiratory Journal recommends starting with CPAP 4-8 cmH2O plus pressure support 10-15 cmH2O for NIV 9
• The target SpO2 is 88-92% in suspected COPD or hypercapnic respiratory failure, as recommended by the British Thoracic Society 6, 7
• NIV should be administered in an ICU setting given the patient's severe acidosis, with intubation readily available 9

Monitoring and Intubation Criteria

• The European Respiratory Journal recommends monitoring for worsening ABG/pH in 1-2 hours on NIV, lack of improvement after 4 hours of NIV, and respiratory rate >35 breaths/min as criteria for intubation 9
• The patient's PCO2 should be monitored closely, and if it rises >1 kPa (7.5 mmHg) despite NIV, intubation should be considered 8, 9

Interpretation and Management of Abnormal Arterial Blood Gas Readings

Special Population Considerations

• The American Association for the Study of Liver Diseases recommends that patients with hepatopulmonary syndrome and PaO2 <60 mmHg should be evaluated for liver transplantation 10
• Severe hypoxemia (PaO2 <45-50 mmHg) in patients with hepatopulmonary syndrome is associated with increased post-transplant mortality, and ABG analysis should be performed every 6 months 10

ABG Interpretation and Management in Critically Ill Patients

Management of Acute Hypercapnic Respiratory Failure

• The British Thoracic Society recommends initiating non-invasive ventilation (NIV) when pH < 7.35 and PaCO2 > 6.5 kPa (49 mmHg) persist despite optimal medical therapy in patients with acute hypercapnic respiratory failure, including those with COPD 11
• Target SpO2 88-92% in all causes of acute hypercapnic respiratory failure, including COPD, and monitor for worsening physiological parameters, particularly pH and respiratory rate, which indicate need to change management strategy 11
• Obtain ABG prior to and following starting NIV, and maximize time on NIV in the first 24 hours depending on patient tolerance, with the goal of normalizing pH and pCO2 11
• Discontinue NIV when pH and pCO2 normalize with general improvement in patient condition, and taper daytime NIV use over 2-3 days depending on pCO2 self-ventilating before discontinuing overnight 11

Critical Pitfalls to Avoid

• Failing to repeat ABG measurements after oxygen therapy changes in patients at risk for CO2 retention is a critical management error, and chest radiography should not delay initiation of NIV in severe acidosis 11
• NIV use should not delay escalation to invasive mechanical ventilation when more appropriate, and severe acidosis alone does not preclude a trial of NIV in an appropriate area with ready access to intubation 11

Management of Acute Hypercapnic Respiratory Failure

Oxygen‑Therapy Targets

• Target arterial oxygen saturation of 88 %–92 % for patients with chronic obstructive pulmonary disease (COPD) and for all causes of acute hypercapnic respiratory failure, using controlled oxygen delivery. 12

Initiation and Monitoring of Non‑Invasive Ventilation (NIV)

• NIV should be started when the arterial pH is < 7.35 and PaCO₂ exceeds 6.5 kPa (≈ 49 mmHg) despite optimal medical therapy. 12
• ABG sampling is required both before initiating NIV and after the device is started to confirm the effect on pH, PaCO₂ and oxygenation. 12
• Oxygen during NIV is titrated from 1 L/min, increasing in 1‑L/min steps, until SpO₂ > 90 % while maintaining the 88 %–92 % target range. 12
• Maximise NIV usage during the first 24 hours, adjusting duration according to patient tolerance, to achieve rapid correction of acid‑base disturbance. 12
• Worsening hypercapnia is defined as a rise in PaCO₂ > 1 kPa (≈ 7.5 mmHg); this signals clinical instability and prompts escalation of therapy. 12
• Deterioration of pH or respiratory rate together with rising PaCO₂ indicates the need to reassess the ventilation strategy. 12

Criteria for Escalation to Invasive Ventilation

• Intubation should be considered if there is no improvement in ABG parameters after 4 hours of NIV, if respiratory rate exceeds 35 breaths/min, or if ABG/pH continues to worsen within 1–2 hours while on NIV. 12
• Severe acidosis alone does not preclude a trial of NIV, provided that immediate access to intubation is available. 12

Discontinuation and Weaning of NIV

• NIV can be stopped once arterial pH and PaCO₂ have normalised and the patient shows overall clinical improvement. 12
• Tapering strategy: reduce daytime NIV use over 2–3 days, guided by PaCO₂ trends, before discontinuing overnight support. 12

Practical Considerations

• Chest radiography should not delay the initiation of NIV in patients with severe acidosis. 12
• NIV must not postpone escalation to invasive mechanical ventilation when it becomes clinically indicated. 12

Alternative Sampling Methods for Gas‑Exchange Monitoring

• Capillary blood gases (CBG) are an acceptable substitute for arterial sampling when re‑measuring PaCO₂ and pH during oxygen‑titration in non‑critical settings. 13
• Transcutaneous CO₂ (PtCO₂) monitoring can be employed if the device is calibrated and its readings are within 10 mm Hg of a concurrent arterial PaCO₂ measurement. 13